ClinicalTrials.gg
Not yet recruitingNCT07392307DED-DMEUpdated Feb 6, 2026

Association Between Dry Eye Disease and Diabetic Macular Edema

An observational study in Dry Eye Disease (DED) , Diabetic Macular Edema, sponsored by Sohag University. Not yet recruiting at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-02-06.

Sponsored by Sohag University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Apr 2026, 6 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
50
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Dry Eye Syndromes with a site in Egypt — 6 open to participants now, 7 under way, none of them phase 3. Dry Eye Syndromes · Egypt.

Started
2026
the only one that year
Observational
7 of 24
2 open now
Registered
21st of 24
by date
Lead sponsor
3 of 24
Sohag University

Among the 24 studies in Dry Eye Syndromes with a site in Egypt, this one is the only one that started in 2026, is one of 7 observational ones, and was the 21st registered.

Dry Eye Syndromes

1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

6 of the 24 studies in Dry Eye Syndromes with a site in Egypt are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →

Who these studies take

Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Dry Eye Syndromes with a site in Egypt, or all of them as a file.
02

Study summary

This study evaluates the association between dry eye disease (DED) and diabetic macular edema (DME) in adult patients at the Ophthalmology Department, Faculty of Medicine, Sohag University. Participants will undergo standardized assessments for dry eye and clinical evaluation for macular edema. The goal is to improve understanding of the relationship between these two eye conditions in patients with diabetes.

Read the detailed description

This prospective observational cross-sectional study investigates the relationship between Dry Eye Disease (DED) and Diabetic Macular Edema (DME) in adult diabetic patients at the Ophthalmology Department, Faculty of Medicine, Sohag University.

Participants undergo comprehensive ocular assessments during a single baseline visit, including:

DED evaluation: Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (TBUT), Schirmer test, and slit-lamp ocular surface examination.

DME assessment: Clinical fundus examination and Optical Coherence Tomography (OCT) imaging.

The study aims to identify associations between anterior segment (ocular surface) parameters and posterior segment pathology (macular edema), to improve understanding of diabetic ocular complications and inform future screening and management strategies.

The study design is cross-sectional (all assessments at a single visit) and prospective regarding enrollment and data collection at baseline.

03

Conditions studied

  • Dry Eye Disease (DED) , Diabetic Macular Edema

Keywords

  • Dry eye disease
  • Diabetic macular edema
  • Diabetes mellitus
  • Ocular surface
  • Optical coherence tomography (OCT)
  • Ophthalmology
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

50 patients with diabetes aged 18-60 years, including 25 patients with diabetic macular edema and 25 patients without macular edema.

Design : This cross-sectional observational study aims to assess ocular and systemic characteristics associated with diabetic macular edema

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18-60 years.
  • Confirmed diagnosis of diabetes mellitus >8 years.
  • Ability to undergo OCT examination.
  • Ability to perform standardized dry eye diagnostic tests.
  • Signed after explanation of study purpose.

Exclusion criteria

Exclusion Criteria:

  • History of ocular surgery.
  • History of Argon laser photocoagulation.
  • Advanced proliferative diabetic retinopathy (PDR): tractional retinal detachment, vitreous hemorrhage, optic neuropathy.
  • Previous significant ocular trauma.
  • Presence of other ocular surface diseases, or history of systemic or ocular surgeries affecting the eye.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
50 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group 1: Participants with Diabetic Macular Edema (DME)

    Participants diagnosed with DME. Dry Eye Disease (DED) will be assessed using imaging and clinical evaluation (OSDI questionnaire, TBUT, Schirmer test, ocular surface examination).

    Diagnostic Test: Dry Eye Disease Assessment

  • Group 2: Participants without DME

    Participants without DME. Dry Eye Disease (DED) will be assessed using imaging and clinical evaluation (OSDI questionnaire, TBUT, Schirmer test, ocular surface examination).

    Diagnostic Test: Dry Eye Disease Assessment

Interventions

  • Diagnostic testDry Eye Disease Assessment

    Assessment of dry eye symptoms, tear film function, and ocular surface examination using standardized questionnaires and clinical tests (OSDI, TBUT, Schirmer test).

06

What researchers measure

Primary outcomes

  1. Dry Eye Disease (DED) Symptom Severity

    DED symptoms will be assessed using the Ocular Surface Disease Index (OSDI) questionnaire to quantify ocular discomfort, visual disturbance, and functional limitations. Units of Measure: OSDI score (0-100)

    Time frame: Baseline (single visit)

  2. Tear Film Function

    Tear film function will be evaluated using Tear Break-Up Time (TBUT) to measure tear film stability and the Schirmer test to assess tear production. Three consecutive measurements are averaged for TBUT; Schirmer test is performed over 5 minutes. Units of Measure: TBUT in seconds; Schirmer test in millimeters (mm)

    Time frame: Baseline (single visit)

  3. Diabetic Macular Edema (DME) Severity

    Diabetic Macular Edema (DME) Severity Description: DME severity will be assessed by clinical fundus examination and Optical Coherence Tomography (OCT) imaging to determine the presence and severity of macular edema. Central macular thickness and retinal fluid are measured. Units of Measure: Macular thickness in micrometers (µm); clinical grading of edema.

    Time frame: Baseline (single visit)

07

Study locations

1 site
08

References and documents

Publications

  • Manaviat MR, Rashidi M, Afkhami-Ardekani M, Shoja MR. Prevalence of dry eye syndrome and diabetic retinopathy in type 2 diabetic patients. BMC Ophthalmol. 2008 Jun 2;8:10. doi: 10.1186/1471-2415-8-10. PubMed 18513455 ↗
  • Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, Liu Z, Nelson JD, Nichols JJ, Tsubota K, Stapleton F. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017 Jul;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008. Epub 2017 Jul 20. PubMed 28736335 ↗

Individual participant data

Plan to share: Undecided — Plans to share Individual Participant Data (IPD) are currently undecided. Any future sharing will follow ethical approvals, institutional policies, and measures to protect participant confidentiality.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Apr 2026, 2 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2026
First posted
Feb 6, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Apr 30, 2026
CompletionEst.
Oct 30, 2026
Last update
Feb 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07392307
Lead sponsor
Sohag University
Responsible party
Esraa Aly (Resident doctor, Ophthalmology department, sohag teaching hospital, Sohag University) — Principal investigator
First posted
Feb 6, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Apr 30, 2026 (estimated)
Completion
Oct 30, 2026 (estimated)
Last update
Feb 6, 2026

Study contacts

Esraa A Ahmed, M.B.B.Ch
Contact
esraaaly@med.sohag.edu.eg
+201022649668
Mohamed I Hafez, MD, PhD
Contact
+201068559840
Islam A Ahmed, MD,PhD
study director · Sohag University, Faculty of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion